Changeflow GovPing Pharma & Drug Safety EPO Patent Publication: Polymer, Crosslinked Bo...
Routine Notice Added Final

EPO Patent Publication: Polymer, Crosslinked Body, Medical Composition

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Biotech (C12N)
Published March 18th, 2026
Detected March 24th, 2026
Email

Summary

The European Patent Office (EPO) has published a patent application (EP2026028918A1) related to polymers, crosslinked bodies, and medical compositions. The publication date is March 18, 2026, and it includes various IPC classifications related to medical materials and polymers.

What changed

The European Patent Office (EPO) has published patent application EP2026028918A1, titled 'POLYMER, CROSSLINKED BODY, MEDICAL COMPOSITION, MEDICAL MATERIAL, METHOD FOR PRODUCING POLYMER, AND METHOD FOR PRODUCING CROSSLINKED BODY'. The publication date is March 18, 2026. The application covers inventions related to polymers, crosslinked bodies, medical compositions, and methods for their production, with numerous IPC classifications indicating relevance to medical materials and drug delivery.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. Companies operating in the biotechnology, pharmaceutical, and medical device sectors should note this publication as it pertains to potential intellectual property in their field. No specific actions are required at this stage, as this is a patent publication, not a regulatory rule or enforcement action.

Source document (simplified)

← EPO Patent Bulletin

POLYMER, CROSSLINKED BODY, MEDICAL COMPOSITION, MEDICAL MATERIAL, METHOD FOR PRODUCING POLYMER, AND METHOD FOR PRODUCING CROSSLINKED BODY

Publication EP2026028918A1 Kind: A1 Mar 18, 2026

Inventors

The designation of the inventor has not yet been filed

IPC Classifications

C08G 69/10 20060101AFI20260207BHEP A61K 31/785 20060101ALI20260207BHEP A61L 15/14 20060101ALI20260207BHEP A61L 15/26 20060101ALI20260207BHEP A61L 15/28 20060101ALI20260207BHEP A61L 15/32 20060101ALI20260207BHEP A61L 17/10 20060101ALI20260207BHEP A61L 24/04 20060101ALI20260207BHEP A61L 24/08 20060101ALI20260207BHEP A61L 24/10 20060101ALI20260207BHEP A61P 7/04 20060101ALI20260207BHEP A61P 9/00 20060101ALI20260207BHEP A61P 9/14 20060101ALI20260207BHEP C08G 69/48 20060101ALI20260207BHEP C08L 77/04 20060101ALI20260207BHEP C08L 101/02 20060101ALI20260207BHEP C12N 9/00 20060101ALI20260207BHEP C12P 21/02 20060101ALI20260207BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP2026028918A1

Who this affects

Applies to
Drug manufacturers Medical device makers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing 3254.1 Biotechnology
Activity scope
Medical Material Development Drug Formulation
Geographic scope
European Union EU

Taxonomy

Primary area
Healthcare
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Medical Devices Pharmaceuticals

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.